Chimeric antigen receptor-T (CAR-T) cell therapy is an evolving treatment entity used to treat relapsed/refractory cancers. It involves genetically modifying autologous or allogeneic T cells to express Chimeric Antigen Receptor (CAR) proteins that target specific cancer cells. Despite promising outcomes, these cells attack normal tissue cells expressing similar proteins on their surfaces. This cross-reactivity results in adverse events (AEs), leading to substantial mortality and morbidity. This activity reviews the evaluation and treatment of CAR-T toxicity and highlights the role of interprofessional teams in evaluating and treating patients with these AEs.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/153034
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABA - 1.0 Point; Credit Type(s): Lifelong Learning (ABA)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS)
ABP - 1.0 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: All Practice Areas (e.g. ethics), Complex General Surgical Oncology, Critical Care Medicine, General Pediatrics, Hospital Medicine, Internal Medicine, Medical Oncology, Neurocritical Care, Pediatric Critical Care Medicine, Pediatric Emergency Medicine, Pediatric Hematology-Oncology, Pediatric Neurology, Surgical Critical Care
Subscribe
Login
0 Comments
Oldest